iSpecimen (NASDAQ:ISPC) Stock Price Down 3.5% – Here’s Why

iSpecimen Inc. (NASDAQ:ISPC) dropped 3.5% during mid-day trading on Thursday . The company traded as low as $0.7502 and last traded at $0.7750. Approximately 140,435 shares traded hands during trading, a decline of 75% from the average daily volume of 572,445 shares. The stock had previously closed at $0.8028.

Analyst Upgrades and Downgrades

ISPC has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of iSpecimen to a “sell” rating in a report on Saturday, September 6th. Weiss Ratings restated a “sell (e+)” rating on shares of iSpecimen in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, iSpecimen presently has an average rating of “Sell”.

iSpecimen Stock Down 3.5%

The company has a market cap of $4.29 million, a price-to-earnings ratio of -0.08 and a beta of 1.81. The company’s fifty day moving average price is $1.06 and its two-hundred day moving average price is $1.12.

iSpecimen (NASDAQ:ISPC) last announced its earnings results on Thursday, August 14th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.80) by $3.38. The business had revenue of $0.71 million for the quarter, compared to analyst estimates of $3.10 million. iSpecimen had a negative return on equity of 395.15% and a negative net margin of 172.48%.

About iSpecimen

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.